Arena Pharmaceuticals Book Value 2011-2026 | ARNA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Arena Pharmaceuticals

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
785 M	1.08 B	1.07 B	606 M	207 M	40.4 M	53.5 M	47.3 M	91.9 M	98.6 M	10.6 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.08 B	10.6 M	372 M

Quarterly Book Value Arena Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	785 M	901 M	1.08 B	1.18 B	1.19 B	1.19 B	1.19 B	1.09 B	1.17 B	1.17 B	1.17 B	1.17 B	687 M	687 M	687 M	687 M	339 M	339 M	339 M	339 M	169 M	169 M	169 M	169 M	257 M	257 M	257 M	257 M	276 M	276 M	276 M	276 M	340 M	340 M	340 M	340 M	261 M	261 M	261 M	261 M	157 M	157 M	157 M	157 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.19 B	157 M	529 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	30.6 M	$ 2.13	-12.55 %	$ 219 M	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
BioCardia BCDA	-1.6 M	$ 1.37	6.2 %	$ 29 M	USA
Black Diamond Therapeutics BDTX	83.3 M	$ 2.4	-2.83 %	$ 132 M	USA
BioLineRx Ltd. BLRX	13.5 M	$ 2.8	-1.06 %	$ 908 M	Israel
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
BioXcel Therapeutics BTAI	-93.1 M	$ 1.64	-1.8 %	$ 4.16 M	USA
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
BeyondSpring BYSI	-14.3 M	$ 1.44	6.3 %	$ 58.1 M	USA
Cabaletta Bio CABA	236 M	$ 3.34	0.6 %	$ 3.9 M	USA
AbCellera Biologics ABCL	967 M	$ 3.7	2.49 %	$ 1.11 B	Canada
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Codexis CDXS	66.9 M	$ 1.05	3.47 %	$ 77.1 M	USA
Cerus Corporation CERS	56.9 M	$ 2.6	1.56 %	$ 480 M	USA
Certara CERT	1.06 B	$ 7.17	1.27 %	$ 1.15 B	USA
Cullinan Management CGEM	590 M	$ 15.91	2.65 %	$ 931 M	USA
Compugen Ltd. CGEN	132 M	$ 2.28	25.97 %	$ 204 M	Israel
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Coherus BioSciences CHRS	-193 M	$ 1.66	-0.9 %	$ 156 M	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Cellectis S.A. CLLS	131 M	$ 3.88	-	$ 116 M	France
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	54.4 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
CNS Pharmaceuticals CNSP	6.18 M	$ 3.1	-0.44 %	$ 1.18 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Cocrystal Pharma COCP	9.52 M	$ 1.02	-0.97 %	$ 10.4 M	USA
Aptose Biosciences APTO	-4.54 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Collegium Pharmaceutical COLL	302 M	$ 42.0	0.79 %	$ 1.33 B	USA
Corcept Therapeutics Incorporated CORT	648 M	$ 35.61	-0.25 %	$ 3.7 B	USA
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA
Aridis Pharmaceuticals ARDS	-24.2 M	-	17.91 %	$ 11.1 M	USA